By Erin Marie Daly ( July 22, 2008, 12:00 AM EDT) -- Merck & Co. and Schering-Plough Corp. are facing an increasingly uphill battle to ward off concerns over their jointly marketed cholesterol treatment Vytorin, with a new study reportedly showing that the blockbuster drug is no more effective than a placebo in treating patients with serious heart conditions....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.